Loading stock…

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

603392Market cap $5.16BPrice $4.0

Country🇨🇳China

SectorHealthcare

IndustryBiotechnology

Develops and manufactures diagnostic reagents and vaccines, including China's first domestically-produced HPV vaccine. Wantai dominates China's in-vitro diagnostics market, supplying testing kits that screen millions for infectious diseases like hepatitis and HIV every year.

In Bastion Portfolios?

52W Return-49%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-46%1

Revenue Forecast

Rev CAGR (1y)+18%8

Rev CAGR (3y)+8%6

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-34%1

Net Income Margin-19%1

Free Cash Flow Margin-25%2

Debt

Net Debt/EBITDAna–

Efficiency

ROE-3%2

ROA-3%2

Earnings Stability33

GEAR+VERY WEAK5

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.95

EV Multiples

EV/EBITDA Fwd1691

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-1.5%2

Dividend Yieldna–

Momentum

Short term

1 month return-1%7

3 month return-2%6

YTD return-39%1

Mid term

Price vs 52wHigh45%1

1 year return-52%1

Long term

3 year return-43%1

5 year return-74%1

Risk Shield

Price Risk

Beta0.48

Volatility37%5

Free Cash Flow

Free Cash Flow Margin-25%2

Free Cash Flow Yield-1.5%2

Quality

ROCE-6%1

Earnings Stability33

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

603392Beijing Wantai Biological Pharmacy Enterprise Co.

Revenue FY25$260M

GROWTH RATING↗

AVERAGE41 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-46%1

Revenue, next 1Y+18%8

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 8%/yr from here.

WATCH

A mid-pack grower, ahead of 41% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Revenue fell 46%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

603392Beijing Wantai Biological Pharmacy Enterprise Co.

Total return Current−62.8%

Price return Current−63.6%

MOMENTUM RATING↗

VERY WEAK11 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-2%6

YTD return-39%1

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-52%1

3-year return-43%1

5-year return-74%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-43% over three years and -74% over five), behind 90% of the market.

It's down 52% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-39%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

603392Beijing Wantai Biological Pharmacy Enterprise Co.

Revenue FY25$260M

GROWTH RATING↗

AVERAGE41 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-46%1

Revenue, next 1Y+18%8

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 8%/yr from here.

WATCH

A mid-pack grower, ahead of 41% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Revenue fell 46%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

603392Beijing Wantai Biological Pharmacy Enterprise Co.

Total return Current−62.8%

Price return Current−63.6%

MOMENTUM RATING↗

VERY WEAK11 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return-2%6

YTD return-39%1

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-52%1

3-year return-43%1

5-year return-74%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-1%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-43% over three years and -74% over five), behind 90% of the market.

It's down 52% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-39%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community